Erratum: Higher 25(OH)D2 is associated with lower 25(OH)D3 and 1,25(OH)2D3 (Journal of Clinical Endocrinology and Metabolism (2014) 99:8 (2736-2744) DOI: 10.1210/jc.2014-1069);Higher 25(OH)D2 is associated with lower 25(OH)D3 and 1,25(OH)2D3

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2736-2744

  Swanson, Christine M ^a,b   Nielson, Carrie M ^b   Shrestha, Smriti ^b   Lee, Christine G ^a,b,c   Barrett Connor, Elizabeth ^d   Jans, Ivo ^e   Cauley, Jane A ^f   Boonen, Steven ^e   Bouillon, Roger ^e   Vanderschueren, Dirk ^e   Orwoll, Eric S ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; CALCIFEDIOL; CALCITRIOL;

AGED; ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; METABOLITE; PRIORITY JOURNAL; QUANTITATIVE STUDY; TANDEM MASS SPECTROMETRY; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

25-HYDROXYVITAMIN D 2; AGED; AGED, 80 AND OVER; BLOOD CHEMICAL ANALYSIS; CALCIFEDIOL; CALCITRIOL; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; MALE; OSTEOPOROTIC FRACTURES; TANDEM MASS SPECTROMETRY;

EID: 84905822892     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3316     Document Type: Erratum

References (30)

1. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96:1911-1930.
2. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
3. Bouillon R, Van Schoor NM, Gielen E, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab. 2013;98:E1283-E1304.
4. Cauley JA, Parimi N, Ensrud KE, et al. Serum 25-hydroxyvitaminD and the risk of hip and nonspine fractures in older men. J Bone Miner Res. 2010;25:545-553.
5. Ensrud KE, Taylor BC, Paudel ML, et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab. 2009;94:2773-2780.
6. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
7. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a metaanalysis of randomised controlled trials. BMJ. 2009;339:b3692.
8. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93:3015-3020.
9. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials. 2005;26:569-585.
10. Blank JB, Cawthon PM, Carrion-Petersen ML, et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials. 2005;26:557-568.
11. Orwoll E, Nielson CM, Marshall LM, et al. Vitamin D deficiency in older men. J Clin Endocrinol Metab. 2009;94:1214-1222.
12. Vanderschueren D, Pye SR, O'Neill TW, et al. Active vitamin D (1, 25-dihydroxyvitamin D) and bone health in middle-aged and elderly men: the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2013;98:995-1005.
13. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: development and validation. Epidemiology. 1990;1:58-64.
14. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol. 1994;10:405-411.
15. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153-162.
16. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766-772.
17. Hollis BW. Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their major metabolites. J Steroid Biochem. 1984;21:81-86.
18. Nilsson SF, Ostberg L, Peterson PA. Binding of vitamin D to its human carrier plasma protein. Biochem Biophys Res Commun. 1972;46:1380-1387.
19. Glendenning P, Chew GT, Inderjeeth CA, Taranto M, Fraser WD. Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol. Bone. 2013;56:271-275.
20. Bouillon R. The vitaminDbinding protein DBP. In: Feldman D, Pike JW, Adams JS, eds. Vitamin D. 3rd ed. Waltham, MA: Academic Press (Elsevier); 2011;57-72.
21. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem. 2003;278:38084-38093.
22. Shinkyo R, Sakaki T, Kamakura M, Ohta M, Inouye K. Metabolism of vitaminDby human microsomal CYP2R1. Biochem Biophys Res Commun. 2004;324:451-457.
23. Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park HW. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol. 2008;380:95-106.
24. ZhuJ, DeLuca HF. VitaminD25-hydroxylase - four decades of searching, are we there yet? Arch Biochem Biophys. 2012;523:30-36.
25. Zhu JG, Ochalek JT, Kaufmann M, Jones G, Deluca HF. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci USA. 2013;110:15650-15655.
26. Aiba I, Yamasaki T, Shinki T, et al. Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases. Steroids. 2006;71:849-856.
27. Demetriou ET, TravisonTG, HolickMF.Treatment with 50, 000 IU vitamin D2 every other week and effect on serum 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and total 25-hydroxyvitamin D in a clinical setting. Endocr Pract. 2012;18:399-402.
28. Nimitphong H, Saetung S, Chanprasertyotin S, Chailurkit LO, Ongphiphadhanakul B. Changes in circulating 25-hydroxyvitamin Daccording to vitaminDbinding protein genotypes after vitaminD3 or D2 supplementation. Nutr J. 2013;12:39.
29. Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. Serum concentrations of 1, 25-dihydroxyvitamin D2 and 1, 25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab. 2013;98:973-979.
30. Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013;98:4339-4345.